Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension.
Saved in:
| Title: | Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension. |
|---|---|
| Authors: | Burger CD; Division of Pulmonary, Allergy and Sleep Medicine, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida., Tang W; Actelion Pharmaceuticals US, Inc, a Johnson & Johnson Company, Titusville, New Jersey., Tsang Y; Actelion Pharmaceuticals US, Inc, a Johnson & Johnson Company, Titusville, New Jersey., Panjabi S; Actelion Pharmaceuticals US, Inc, a Johnson & Johnson Company, Titusville, New Jersey. |
| Source: | JAMA network open [JAMA Netw Open] 2024 Sep 03; Vol. 7 (9), pp. e2434691. Date of Electronic Publication: 2024 Sep 03. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
